Periostin as a predictor of severe exacerbations in asthma

A study to determine periostin as a predictor of severe exacerbations in asthma in adult asthmatics

Status

Completed

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12615000503527

Acronym

PER09

Enrollment

212

Registered

2015-05-20

Start date

2015-05-28

Completion date

2016-06-15

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Levels of POSTN (periostin coding gene, also known as osteoblast specific factor) gene expression and periostin have been measured in a number of tissues and disease states, including asthma. As yet, an incomplete picture is currently available on the role and effects of periostin level in the blood, however it has shown promise as a biomarker for asthma severity and a marker of inflammation levels, being easy to measure through a simple blood test. This study will assess the use of periostin as a predictor of severe asthma exacerbations in pre-existing cohorts of adults with a diagnosis of asthma and compare this to currently used markers such as blood eosinophil counts, serum IgE and FeNO. The cohorts include patients across a range of disease severity.

Interventions

Serum periostin levels in adult asthmatics will be measured at a single visit via a specific periostin assay. The periostin level will be compared to a sample taken at the baseline assessment, when the participant attended the Medical Research Insitute for the New Zealand Respiratory Health Survey (NZRHS) study and the Longitudinal study of periostin levels in asthma (PER02), occurring 1 to 5 years ago.

Eligibility

Sex/Gender

All

Age

18 Years to 95 Years

Healthy volunteers

Inclusion criteria

Participants from: -New Zealand Respiratory Health Survey (NZRHS) (ACTR number 12610000666022) phase two and -Longitudinal study of serum periostin levels in asthma (PER02)(ACTR number 12614000235606) Able to perform written informed consent

Exclusion criteria

-Known pregnancy -Surgery within last 3 months, determined at investigator discretion (this includes all major surgery requiring general anaesthetic, dental extractions and root canal procedures. This does not include minor procedures including, but not limited to, mole or wart removal, dental fillings etc) -Bone fracture within last 3 months -Active (current, or within the 3 weeks prior to the visit) upper or lower respiratory tract infection -Any other safety concern at the investigator's discretion

Outcome results